No Data
Tofflon Science and Technology Group (300171.SZ): Can provide Global pharmaceutical companies with integrated intelligent solutions for equipment + consumables + engineering.
On February 12, Glonghui reported that Tofflon Science and Technology Group (300171.SZ) stated on the investor interaction platform that the company has been deeply involved in the Biomedical Industry for over thirty years, adhering to the mission of "providing professional technical services for Biomedical" and is committed to becoming a provider of smart pharmaceutical factories. The company can offer Global pharmaceutical enterprises integrated smart solutions that include equipment, consumables, and engineering.
Tofflon Science and Technology Group Co., Ltd.'s (SZSE:300171) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Tofflon Science and Technology Group to Co-Invest 200 Million Yuan in Biopharmaceutical M&A Fund
Tofflon Science and Technology Group (300171.SZ) intends to invest 0.2 billion yuan to participate in the establishment of the Shanghai Biomedical Merger Fund.
Tofflon Science and Technology Group (300171.SZ) issued an announcement to promote the company's long-term development and fully leverage the expertise of professional investment Institutions...
Tofflon Science and Technology Group (300171.SZ): Net income for the year 2024 is expected to decrease by 60.85% - 69.18%.
According to Gelonghui on January 24, Tofflon Science and Technology Group (300171.SZ) announced its performance forecast for the year 2024, expecting a Net income attributable to Shareholders of the listed company to be between 0.185 billion yuan and 0.235 billion yuan, a decrease of 60.85% to 69.18% compared to the same period last year; the Net income attributable to Shareholders of the listed company, after deducting non-recurring gains and losses, is expected to be between 105 million yuan and 155 million yuan, a decrease of 72.17% to 81.15% compared to the same period last year. During the reporting period, the company's performance declined mainly due to the slowdown in the domestic Biomedical industry’s investment pace in fixed assets, which affected the demand for pharmaceutical equipment.
Dongfulong: 2024 performance forecast
Benign Growth For Tofflon Science and Technology Group Co., Ltd. (SZSE:300171) Underpins Stock's 26% Plummet
